Gilead looks attractive again. Its innovative edge and new crop of medications are performing well across multiple ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...

Gilead delays Biktarvy generics until 2036, boosting its competitive edge and projected stock gains. Read more here.

Gilead Sciences said it has reached settlements with multiple drug manufacturers that had sought to market generic versions of Biktarvy, its treatment for human immunodeficiency virus, or HIV.